Anti-Complement component C5b-9 (human)
Mouse monoclonal antibody
Cat.No. DIA 011-01
Preparation: Protein-A purified
Content: Available in 200 µL and 1 mL size.1 mg/mL +/- 15%. See Certificate of Analysis for details.
Solvent: 10 mM phosphate buffer pH 7.4 containing 0.15 M NaCl and 0.09% sodium azide
Storage: 4-8ºC without exposure to light. No precautions necessary during handling.
C5b-9 is also known as the terminal complement complex (TCC). The TCC consists of C5b, C6, C7, C8 and C9 and forms the membrane attack complex (MAC) as well as the non-lytic fluid-phase SC5b-9 complex (with protein S). The MAC forms channels in target cell membranes leading to cell lysis by osmotic leakage. The complexes contain neoantigens that are absent from the individual native components from which they are formed and DIA 011-01 is directed against a neoepitope exposed on C9 when incorporated into the TCC (1,2).
Purified C5b-9
DIA 011-01 binds both membrane-bound MAC and fluid-phase SC5b-9 complexes. DIA 011-01 cross-reacts with porcine (3), baboon (4) and equine TCC.
DIA 011-01 binds to a neoepitope exposed on C9
DIA 011-01 is well suited for quantifying TCC in ELISA and quantifying and characterizing TCC in various tissues by immunohistochemistry (frozen and paraffin sections). DIA 011-01 is not recommended for Western blotting as the epitope is destroyed during the process (1).
| Method | Usability | References |
| ELISA | Yes | 5,6 |
| Immunoblotting | No | 1 |
| Immunohistochemistry | Yes | 7,8,9 |
1. Mollnes TE, Lea T, Harboe M, Tschopp J (1985) Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 22:183-195.
2. Drogari-Aspiranthitou M, Kuijper EJ, Dekker N, Dankert J (2002) Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity. Infect Immunol 70:3752-3758.
3. Jansen JH, Høgåsen K, Mollnes TE (1993) Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol 143:1356-1365.
4. Mollnes TE, Redl H, Høgåsen K, Bengtsson A, Garred P, Speilberg L, Lea T, Oppermann M, Götze O, Schlag G (1993)
Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC).Clin Exp Immunol 91:295-300.
5. Mollnes TE, Lea T, Frøland SS, Harbroe M (1985) Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 22:197-202.
6. Mollnes TE (1997) Analysis of in vivo complement activation. Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C: Weir's Handbook of Experimental Immunology. Boston, MA: Blackwell Science, pp. 78.1-78.8.
7. Halstensen TS, Mollnes TE, Fausa O, Brandtzaeg P (1989) Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. Gut 30:361-6.
8. Halstensen TS, Mollnes TE, Brandtzaeg P (1989) Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology 97:10-9.
9. Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P (1990) Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 98:1264-71.
Downloads
DIA 011-01.pdf (32.24 kB) Product specification
ELISA Kits and Monoclonal antibodies for the Complement system - flyer.pdf (637.76 kB)
ELISA Kits and Monoclonal antibodies for the Complement system
Related Articles
Antibody MSDS
April 23 2008
